3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
10
Terminated
5
Withdrawn
2
Recruiting
2
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Colorectal Neoplasms
43
Squamous Cell Carcinoma of Head and Neck
12
Rectal Neoplasms
12
Colonic Neoplasms
11
Neoplasm Metastasis
9
Head and Neck Neoplasms
8
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Colorectal Cancer Metastatic
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Oropharyngeal Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Carcinoma, Squamous Cell
2
mCRC
1
Stomach Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Metastasis Colon Cancer
1
Incurable Colorectal Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Cetuximab
×
Clear all
NCT02624128
2023-11-13
V-CHANCE
National Cancer Institute, Naples
Phase 2
Unknown
39 enrolled